Shutdown of HIV-1 transcription in T cells by Nullbasic, a mutant tat protein

mBio

Volumn 7, Issue 4, 2016, Pages

  Jin, Hongping ^a   Li, Dongsheng ^a   Sivakumaran, Haran ^a   Lor, Mary ^a   Rustanti, Lina ^a   Cloonan, Nicole ^a   Wani, Shivangi ^a   Harrich, David ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; DNA DIRECTED RNA POLYMERASE III; HISTONE H3; HISTONE H3 LYSINE 9; HYBRID PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; NULLBASIC PROTEIN; NULLBASIC ZSGREEN1 FUSION PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; ANTIVIRUS AGENT; MUTANT PROTEIN;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; COCULTURE; CONTROLLED STUDY; HISTONE ACETYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; JURKAT CELL LINE; LONG TERMINAL REPEAT; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; T LYMPHOCYTE; TRANSCRIPTOMICS; VIRUS CAPSID; VIRUS LATENCY; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; HIV INFECTIONS; HUMAN; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; MUTANT PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84986551098     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00518-16     Document Type: Article

References (53)

1. Van Lint C, Bouchat S, Marcello A. 2013. HIV-1 transcription and latency: an update. Retrovirology 10:67. http://dx.doi.org/10.1186/1742-4690-10-67.
2. Coffin JM, Huges SH, Varmus HE. 1997. Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
3. Garber ME, Wei P, Jones KA. 1998. HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Cold Spring Harb Symp Quant Biol 63:371-380. http://dx.doi.org/10.1101/sqb.1998.63.371.
4. Sobhian B, Laguette N, Yatim A, Nakamura M, Levy Y, Kiernan R, Benkirane M. 2010. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell 38:439-451. http://dx.doi.org/10.1016/j.molcel.2010.04.012.
5. Ott M, Geyer M, Zhou Q. 2011. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 10:426-435. http://dx.doi.org/10.1016/j.chom.2011.11.002.
6. Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J, Cron RQ, van der Sluis RM, Jeeninga RE, Berkhout B, Kutsch O. 2013. An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol 87: 2264-2277. http://dx.doi.org/10.1128/JVI.01594-12.
7. Verdin E, Paras P, Jr., Van Lint C. 1993. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249-3259. (Erratum, 12:4900, 1993.)
8. Van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112-1120.
9. + T cells. PLoS Pathog 2:e68. http://dx.doi.org/10.1371/journal.ppat.0020068.
10. Kula A, Marcello A. 2012. Dynamic post-transcriptional regulation of HIV-1 gene expression. Biology (Basel) 1:116-133. http://dx.doi.org/10.3390/biology1020116.
11. Kula A, Guerra J, Knezevich A, Kleva D, Myers MP, Marcello A. 2011. Characterization of the HIV-1RNAassociated proteome identifies matrin 3 as a nuclear cofactor of rev function. Retrovirology 8:60. http://dx.doi.org/10.1186/1742-4690-8-60.
12. Dayton AI. 2011. Matrin 3 and HIV Rev regulation of mRNA. Retrovirology 8:62. http://dx.doi.org/10.1186/1742-4690-8-62.
13. Kula A, Gharu L, Marcello A. 2013. HIV-1 pre-mRNA commitment to rev mediated export through PSF and matrin 3. Virology 435:329-340. http://dx.doi.org/10.1016/j.virol.2012.10.032.
14. Yedavalli VS, Jeang KT. 2011. Matrin 3 is a co-factor for HIV-1 Rev in regulating post-transcriptional viral gene expression. Retrovirology 8:61. http://dx.doi.org/10.1186/1742-4690-8-61.
15. Dahabieh MS, Battivelli E, Verdin E. 2015. Understanding HIV latency: the road to an HIV cure. Annu Rev Med 66:407-421. http://dx.doi.org/10.1146/annurev-med-092112-152941.
16. Ruelas DS, Greene WC. 2013. An integrated overview of HIV-1 latency. Cell 155:519-529. http://dx.doi.org/10.1016/j.cell.2013.09.044.
17. Chavez L, Calvanese V, Verdin E. 2015. HIV latency is established directly and early in both resting and activated primary CD4 T cells. PLoS Pathog 11:e1004955. http://dx.doi.org/10.1371/journal.ppat.1004955.
18. Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. 2015. A hardwired HIV latency program. Cell 160:990-1001. http://dx.doi.org/10.1016/j.cell.2015.02.009.
19. Karn J, Stoltzfus CM. 2012. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med 2:a006916. http://dx.doi.org/10.1101/cshperspect.a006916.
20. Meredith LW, Sivakumaran H, Major L, Suhrbier A, Harrich D. 2009. Potent inhibition of HIV-1 replication by a Tat mutant. PLoS One 4:e7769. http://dx.doi.org/10.1371/journal.pone.0007769.
21. + T cells. Hum Gene Ther 24:270-282. http://dx.doi.org/10.1089/hum.2012.176.
22. Lin MH, Apolloni A, Cutillas V, Sivakumaran H, Martin S, Li D, Wei T, Wang R, Jin H, Spann K, Harrich D. 2015. A mutant Tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex. J Virol 89:4827-4836. http://dx.doi.org/10.1128/JVI.03440-14.
23. Lin MH, Sivakumaran H, Jones A, Li D, Harper C, Wei T, Jin H, Rustanti L, Meunier FA, Spann K, Harrich D. 2014. A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1. Retrovirology 11:121. http://dx.doi.org/10.1186/s12977-014-0121-9.
24. Lin MH, Sivakumaran H, Apolloni A, Wei T, Jans DA, Harrich D. 2012. Nullbasic, a potent anti-HIV Tat mutant, induces CRM1-dependent disruption of HIV Rev trafficking. PLoS One 7:e51466. http://dx.doi.org/10.1371/journal.pone.0051466.
25. Salomonis N, Schlieve CR, Pereira L, Wahlquist C, Colas A, Zambon AC, Vranizan K, Spindler MJ, Pico AR, Cline MS, Clark TA, Williams A, Blume JE, Samal E, Mercola M, Merrill BJ, Conklin BR. 2010. Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci U S A 107:10514-10519. http://dx.doi.org/10.1073/pnas.0912260107.
26. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663. http://dx.doi.org/10.1146/annurev.immunol.18.1.621.
27. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. 2012. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92:1147-1154. http://dx.doi.org/10.1189/jlb.0312165.
28. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495. http://dx.doi.org/10.1371/journal.ppat.1000495.
29. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868-1877. http://dx.doi.org/10.1093/emboj/cdg188.
30. Tréand C, du Chéné I, Brès V, Kiernan R, Benarous R, Benkirane M, Emiliani S. 2006. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J 25: 1690-1699. http://dx.doi.org/10.1038/sj.emboj.7601074.
31. Mahmoudi T, Parra M, Vries RG, Kauder SE, Verrijzer CP, Ott M, Verdin E. 2006. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem 281: 19960-19968. http://dx.doi.org/10.1074/jbc.M603336200.
32. Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F. 2006. Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology 3:48. http://dx.doi.org/10.1186/1742-4690-3-48.
33. Jablonski JA, Amelio AL, Giacca M, Caputi M. 2010. The transcriptional transactivator Tat selectively regulates viral splicing. Nucleic Acids Res 38:1249-1260. http://dx.doi.org/10.1093/nar/gkp1105.
34. Bennasser Y, Jeang KT. 2006. HIV-1 Tat interaction with dicer: requirement for RNA. Retrovirology 3:95. http://dx.doi.org/10.1186/1742-4690-3-95.
35. Hayes AM, Qian S, Yu L, Boris-Lawrie K. 2011. Tat RNA silencing suppressor activity contributes to perturbation of lymphocyte miRNA by HIV-1. Retrovirology 8:36. http://dx.doi.org/10.1186/1742-4690-8-36.
36. Warrilow D, Harrich D. 2007. HIV-1 replication from after cell entry to the nuclear periphery. Curr HIV Res 5:293-299. http://dx.doi.org/10.2174/157016207780636579.
37. Charbonneau J, Gendron K, Ferbeyre G, Brakier-Gingras L. 2012. The 5=UTRof HIV-1 full-lengthmRNAand the Tat viral protein modulate the programmed ―1 ribosomal frameshift that generates HIV-1 enzymes. RNA 18:519-529. http://dx.doi.org/10.1261/rna.030346.111.
38. Jeang KT. 2012. Multi-faceted post-transcriptional functions of HIV-1 Rev. Biology (Basel) 1:165-174. http://dx.doi.org/10.3390/biology1020165.
39. Green M, Ishino M, Loewenstein PM. 1989. Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58:215-223. http://dx.doi.org/10.1016/0092-8674(89)90417-0.
40. Pearson L, Garcia J, Wu F, Modesti N, Nelson J, Gaynor R. 1990. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A 87:5079-5083. http://dx.doi.org/10.1073/pnas.87.13.5079.
41. Modesti N, Garcia J, Debouck C, Peterlin M, Gaynor R. 1991. Transdominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol 3:759-768.
42. Ulich C, Harrich D, Estes P, Gaynor RB. 1996. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins. J Virol 70:4871-4876.
43. Willemsen NM, Hitchen EM, Bodetti TJ, Apolloni A, Warrilow D, Piller SC, Harrich D. 2006. Protein methylation is required to maintain optimal HIV-1 infectivity. Retrovirology 3:92. http://dx.doi.org/10.1186/1742-4690-3-92.
44. Sivakumaran H, Lin MH, Apolloni A, Cutillas V, Jin H, Li D, Wei T, Harrich D. 2013. Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6. Virol J 10:207. http://dx.doi.org/10.1186/1743-422X-10-207.
45. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D. 2009. Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol 83:11694-11703. http://dx.doi.org/10.1128/JVI.00499-09.
46. Xie B, Invernizzi CF, Richard S, Wainberg MA. 2007. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat interactions with both cyclin T1 and the Tat transactivation region. J Virol 81:4226-4234. http://dx.doi.org/10.1128/JVI.01888-06.
47. Jeang KT, Chun R, Lin NH, Gatignol A, Glabe CG, Fan H. 1993. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol 67:6224-6233.
48. Widlak P, Gaynor RB, Garrard WT. 1997. In vitro chromatin assembly of the HIV-1 promoter. ATP-dependent polar repositioning of nucleosomes by Sp1 and NFkappaB. J Biol Chem 272:17654-17661. http://dx.doi.org/10.1074/jbc.272.28.17654.
49. Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST. 2015. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. mBio 6:e00465. http://dx.doi.org/10.1128/mBio.00465-15.
50. Karn J. 2011. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS 6:4-11. http://dx.doi.org/10.1097/COH.0b013e328340ffbb.
51. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
52. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. 1996. A dual-tropic primary HIV-1 isolate that uses fusion and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158. http://dx.doi.org/10.1016/S0092-8674(00)81314-8.
53. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S. 1996. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol 70:3863-3869.